These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 19428220

  • 1. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.
    Livermore DM, Mushtaq S, Ge Y, Warner M.
    Int J Antimicrob Agents; 2009 Nov; 34(5):402-6. PubMed ID: 19428220
    [Abstract] [Full Text] [Related]

  • 2. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.
    Zamorano L, Juan C, Fernández-Olmos A, Ge Y, Cantón R, Oliver A.
    Clin Microbiol Infect; 2010 Sep; 16(9):1482-7. PubMed ID: 20002107
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
    Mushtaq S, Warner M, Livermore DM.
    J Antimicrob Chemother; 2010 Nov; 65(11):2376-81. PubMed ID: 20801783
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
    Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A.
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1213-7. PubMed ID: 20086158
    [Abstract] [Full Text] [Related]

  • 6. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters.
    Mushtaq S, Warner M, Livermore D.
    J Antimicrob Chemother; 2010 Feb; 65(2):266-70. PubMed ID: 19996139
    [Abstract] [Full Text] [Related]

  • 7. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S, Ge Y, Livermore DM.
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [Abstract] [Full Text] [Related]

  • 8. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
    Livermore DM, Mushtaq S, Ge Y.
    J Antimicrob Chemother; 2010 Sep; 65(9):1972-4. PubMed ID: 20595207
    [Abstract] [Full Text] [Related]

  • 9. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.
    Riera E, Macià MD, Mena A, Mulet X, Pérez JL, Ge Y, Oliver A.
    J Antimicrob Chemother; 2010 Jul; 65(7):1399-404. PubMed ID: 20435779
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
    Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K.
    Antimicrob Agents Chemother; 2007 Mar; 51(3):826-30. PubMed ID: 17145788
    [Abstract] [Full Text] [Related]

  • 12. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H, Sáenz Y, Nichols WW, Tulkens PM, Van Bambeke F.
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM, Brown SD.
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [Abstract] [Full Text] [Related]

  • 14. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.
    Llanes C, Pourcel C, Richardot C, Plésiat P, Fichant G, Cavallo JD, Mérens A, GERPA Study Group.
    J Antimicrob Chemother; 2013 Aug; 68(8):1763-71. PubMed ID: 23629014
    [Abstract] [Full Text] [Related]

  • 15. [Antibiotic susceptibility rates and beta-lactam resistance mechanisms of Pseudomonas aeruginosa strains].
    Aktaş Z, Satana D, Kayacan C, Can B, Gönüllü N, Küçükbasmacı O.
    Mikrobiyol Bul; 2012 Jul; 46(3):386-97. PubMed ID: 22951651
    [Abstract] [Full Text] [Related]

  • 16. Extended-spectrum and metallo-beta-lactamases among ceftazidime-resistant Pseudomonas aeruginosa in Riyadh, Saudi Arabia.
    Al-Agamy MH, Shibl AM, Tawfik AF, Elkhizzi NA, Livermore DM.
    J Chemother; 2012 Apr; 24(2):97-100. PubMed ID: 22546765
    [Abstract] [Full Text] [Related]

  • 17. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa.
    Giske CG, Ge J, Nordmann P.
    J Antimicrob Chemother; 2009 Aug; 64(2):430-1. PubMed ID: 19474066
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward.
    Döring G, Jansen S, Noll H, Grupp H, Frank F, Botzenhart K, Magdorf K, Wahn U.
    Pediatr Pulmonol; 1996 Feb; 21(2):90-100. PubMed ID: 8882212
    [Abstract] [Full Text] [Related]

  • 20. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A.
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.